SCHEMBL714764

SCHEMBL714764

O=[N+]([O-])C(O)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPA1 P15085 7/20 0.53
CYP1A2 P05177 1/20 0.47
ALPI P09923 1/20 0.44
PKM P14618 1/20 0.44
PTGS1 P23219 1/20 0.44
XIAP P98170 1/20 0.44
SLC7A5 Q01650 1/20 0.44
ALPL P05186 1/20 0.43
POLB P06746 1/20 0.43
ALPG P10696 1/20 0.43
MDM2 Q00987 1/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
EPHX1 P07099 1/20 0.41
ANPEP P15144 1/20 0.41
LAP3 P28838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16390246 0.80 TSHR (0.53) CYP1A2POLBCES1
SCHEMBL19025403 0.80 ANPEP (0.44) CPA1CYP1A2POLBANPEP
SCHEMBL9672469 0.79 FOLH1 (0.54) TP53ANPEP
Nitric Acid SCHEMBL9873353 0.79 CPA1 (0.53) CPA1CYP1A2ALPIPKMPTGS1
SCHEMBL187342 0.78 CPA1 (0.52) CPA1CYP1A2ALPIPKMPTGS1
SCHEMBL27952504 0.78 TSHR (0.57) CYP1A2POLBTP53SMN1; SMN2CES2
SCHEMBL6108470 0.78 NR3C1 (0.45) CYP1A2POLBNPC1RAB9A
SCHEMBL8540021 0.77 SLC15A1 (0.49) CPA1ALPIPKMPTGS1XIAP
SCHEMBL5610245 0.77 CPA1 (0.50) CPA1CYP1A2ALPIPKMPTGS1
SCHEMBL5981148 0.76 CPA1 (0.50) CPA1CYP1A2ALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025007135-A9 CONTROLLED GLYCAN METABOLIC ENGINEERING SYSTEMS AND APPLICATIONS THEREOF WAYNE STATE UNIVERSITY (US) 2025-03-27 WO claimed
WO-2025007135-A2 CONTROLLED GLYCAN METABOLIC ENGINEERING SYSTEMS AND APPLICATIONS THEREOF WAYNE STATE UNIVERSITY (US) 2025-01-02 WO claimed
CN-109126823-A Nitrobenzene selective hydrogenation prepares the catalyst and preparation method, application of aniline 江西理工大学 2019-01-04 CN claimed
CN-109053453-A A kind of synthetic method of α-o-nitrophenylethanol 江苏师范大学 2018-12-21 CN claimed
CN-108160094-A A kind of N doping Carbon Materials support noble metal catalyst and preparation and application 中国科学院大连化学物理研究所 2018-06-15 CN claimed
CN-107537565-A Cross linked amphoteric polymeric supported precious metal catalyst and preparation and alcohol method for oxidation 中国科学院大连化学物理研究所 2018-01-05 CN claimed
CN-105363394-B A kind of preparation and application of the magnetic fluorescence molecular engram nanoparticle for detecting nitrobenzene 济南大学 2017-11-07 CN claimed
EP-2486115-B1 ELECTRORHEOLOGIC FLUID COMPRISING ORGANIC SUBSTANCES THAT CAN BE DOPED AND USE THEREOF FRAUNHOFER GES FORSCHUNG (DE) 2015-05-20 EP claimed
EP-2486115-A1 ELECTRORHEOLOGICAL FLUID COMPRISING ORGANIC DOPANTS, AND USE THEREOF Fraunhofer Gesellschaft zur Förderung der angewandten Wissenschaft E.V. (DE) 2012-08-15 EP claimed
WO-2011042117-A1 ELECTRORHEOLOGICAL FLUID COMPRISING ORGANIC DOPANTS, AND USE THEREOF Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2011-04-14 WO claimed
EP-3808786-B1 DEGRADABLE MICROSPHERE AND USE THEREOF UNIV TSINGHUA (CN) 2025-09-10 EP disclosed
US-12325767-B2 Degradable microsphere and use thereof TSINGHUA UNIVERSITY (CN) 2025-06-10 US disclosed
WO-2025007135-A9 CONTROLLED GLYCAN METABOLIC ENGINEERING SYSTEMS AND APPLICATIONS THEREOF WAYNE STATE UNIVERSITY (US) 2025-03-27 WO disclosed
WO-2025007135-A2 CONTROLLED GLYCAN METABOLIC ENGINEERING SYSTEMS AND APPLICATIONS THEREOF WAYNE STATE UNIVERSITY (US) 2025-01-02 WO disclosed
CN-116676354-A Method for synthesizing indigo and derivative thereof through double-enzyme cascade catalysis 南京工业大学 2023-09-01 CN disclosed
US-4698340-A TREATMENT OF CEREBROVASCULAR DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1987-10-06 US disclosed
US-4581178-A USING TRANSITION METAL COMPLEXES CONTAINING PHOSPHINE OR ARSINE LI E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-04-08 US disclosed
EP-0169712-A2 New pyrimidine derivatives, processes for preparation thereof and composition containing the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-01-29 EP disclosed
US-4374061-A ACTIVATION, AMINATION, AND DIAZOTIZATION OF A POLYSACCHARIDE FOLLOWED BY REACTION WITH A GLOBULIN; CHROMATOGRAPHY; SEPARATION OF GLYCOPROTEINS CENTER FOR BLOOD RESEARCH, INC. (US) 1983-02-15 US disclosed
US-4299992-A Process for the selective hydroxymethylation of nitrotoluenes REANAL FINOMVEGYSZERGYAR (HU) 1981-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12325767-B2 Degradable microsphere and use thereof STUB1, PSMD14, ACP1 CPA1 1447/4885CYP1A2 4564/4885ALPI 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.